NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $30.72 +0.13 (+0.42%) Closing price 04:00 PM EasternExtended Trading$30.64 -0.08 (-0.28%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tectonic Therapeutic Stock (NASDAQ:TECX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$30.49▼$31.6150-Day Range$26.87▼$31.1752-Week Range$14.39▼$36.03Volume95,754 shsAverage Volume133,517 shsMarket Capitalization$579.69 millionP/E RatioN/ADividend YieldN/APrice Target$79.40Consensus RatingBuy Company Overview Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. Read More Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreTECX MarketRank™: Tectonic Therapeutic scored higher than 49% of companies evaluated by MarketBeat, and ranked 458th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingTectonic Therapeutic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTectonic Therapeutic has a consensus price target of $79.40, representing about 158.5% upside from its current price of $30.72.Amount of Analyst CoverageTectonic Therapeutic has only been the subject of 3 research reports in the past 90 days.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($5.46) to ($5.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tectonic Therapeutic's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.61% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 10.59, which indicates bearish sentiment.Change versus previous monthShort interest in Tectonic Therapeutic has recently decreased by 10.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tectonic Therapeutic this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TECX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,000.00 in company stock.Percentage Held by Insiders39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECX Stock News HeadlinesTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from BrokeragesJune 18, 2026 | americanbankingnews.comTectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF PatientsJune 10, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.June 24 at 1:00 AM | Porter & Company (Ad)Tectonic Therapeutic Inc TECXMay 31, 2026 | morningstar.comMRaymond James upgrades Tectonic Therapeutic (TECX)May 27, 2026 | msn.comTectonic Therapeutics: Currently In A Catalyst VacuumMay 19, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Tectonic Therapeutic (TECX)May 17, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)May 11, 2026 | theglobeandmail.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $20.86 at the beginning of the year. Since then, TECX stock has increased by 47.3% and is now trading at $30.72. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic, Inc. (NASDAQ:TECX) issued its earnings results on Thursday, May, 7th. The company reported ($1.34) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by $0.18. When did Tectonic Therapeutic IPO? Tectonic Therapeutic (TECX) raised $89 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,247,958 shares at $16.00-$18.00 per share. Who are Tectonic Therapeutic's major shareholders? Top institutional shareholders of Tectonic Therapeutic include First Light Asset Management LLC (3.43%), Orbimed Advisors LLC (1.20%), Sei Investments Co. (0.20%) and Bank of New York Mellon Corp (0.13%). Insiders that own company stock include Timothy A Springer, Marcella K Ruddy, Peter Mcnamara and Daniel Lochner. View institutional ownership trends. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tectonic Therapeutic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tectonic Therapeutic investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today6/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 TECX's financial health is in the Green zone, according to TradeSmith. TECX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.avrobio.com Phone617-914-8420FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Tectonic Therapeutic$79.40 High Price Target$101.00 Low Price Target$60.00 Potential Upside/Downside+158.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-32.33% Return on Assets-30.92% Debt Debt-to-Equity RatioN/A Current Ratio18.51 Quick Ratio18.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.43 per share Price / Book2.29Miscellaneous Outstanding Shares18,870,000Free Float11,359,000Market Cap$579.69 million OptionableN/A Beta3.19 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:TECX) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
